BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36996787)

  • 1. Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib.
    SahBandar IN; Sy CB; van den Akker T; Kim D; Geyer JT; Chadburn A; Cesarman E; Inghirami G; Allan JN; Siddiqui MT; Ouseph MM
    Pathobiology; 2023; 90(5):356-364. PubMed ID: 36996787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
    Kojima M; Nakamura N; Amaki J; Numata H; Miyaoka M; Motoori T; Matsumoto K; Ando K
    J Clin Exp Hematop; 2017; 57(2):69-73. PubMed ID: 29021516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.
    Christe L; Veloza L; Gros L; Bisig B; Blum S; Hewer E; de Leval L
    Diagn Cytopathol; 2022 Dec; 50(12):E351-E356. PubMed ID: 35916333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spontaneous regression of dasatinib-related primary effusion lymphoma-like lymphoma.
    Hayashino K; Meguri Y; Yukawa R; Komura A; Nakamura M; Yoshida C; Yamamoto K; Oda W; Imajo K
    Int J Hematol; 2023 Jan; 117(1):137-142. PubMed ID: 36066839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib-related effusion lymphoma in a patient treated for chronic myeloid leukaemia.
    Miyagi D; Chen WY; Chen BJ; Su YZ; Kuo CC; Karube K; Chuang SS
    Cytopathology; 2020 Nov; 31(6):602-606. PubMed ID: 32681657
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia.
    Suyama T; Hagihara M; Matsui N; Irie R; Osamura Y; Sakai T; Watanabe S; Umemoto S; Miyao N
    J Clin Exp Hematop; 2023 Mar; 63(1):43-48. PubMed ID: 36843069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders.
    Ramaswami R; Lurain K; Marshall VA; Rupert A; Labo N; Cornejo-Castro E; Miley W; Wang HW; Widell A; Lindsley M; Yuan C; Stetler-Stevenson M; Filie AC; Whitby D; Ziegelbauer JM; Uldrick TS; Yarchoan R
    AIDS; 2021 Jan; 35(1):53-62. PubMed ID: 33273183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8-associated extracavitary primary effusion lymphoma presenting as multiple lymphomatous polyposis.
    Oster C; Stein T; Kitahara S; Alkan S; Huang Q
    Hum Pathol; 2018 Sep; 79():177-183. PubMed ID: 29505765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.
    Foster WR; Bischin A; Dorer R; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):311-21. PubMed ID: 27234438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy.
    McBride A; Brokars J; Reddy SR; Chang E; Tarbox MH; LeBlanc TW
    Acta Haematol; 2023; 146(4):259-266. PubMed ID: 37037194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
    Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
    J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
    Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
    mBio; 2018 May; 9(3):. PubMed ID: 29739902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KSHV-associated extracavitary primary effusion lymphoma in an HIV seronegative patient: a case report and review of the literature.
    Ibrahim U; Saqib A; Mohammad F; Ding J; Hussein S; Atallah JP
    Postgrad Med; 2017 Apr; 129(3):402-407. PubMed ID: 28122468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
    Naqvi K; Jabbour E; Skinner J; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
    Cancer; 2018 Jul; 124(13):2740-2747. PubMed ID: 29723397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KHSV(-) EBV(-) post-transplant effusion lymphoma with plasmablastic features: variant of primary effusion lymphoma?
    Lambe JS; Oble DA; Nandula SV; Sevilla DW; Colovai AI; Mansukhani M; Chari A; Murty VV; Alobeid B; Bhagat G
    Hematol Oncol; 2009 Dec; 27(4):203-10. PubMed ID: 19337983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib-induced Chylothorax in Chronic Myeloid Leukemia.
    Alqattan Y; Ali S; Almohammad R; Kayali N; Alhuraiji A
    Gulf J Oncolog; 2022 Sep; 1(40):74-77. PubMed ID: 36448074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases.
    Fiori S; Todisco E; Ramadan S; Gigli F; Falco P; Iurlo A; Rampinelli C; Croci G; Pileri SA; Tarella C
    Biology (Basel); 2021 Feb; 10(2):. PubMed ID: 33672947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
    Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.